RetCAD

Nijmegen, Netherlands

Diagnostics & Monitoring Imaging Diagnostics Ophthalmology Digital Diagnostics

With global costs of vision loss estimated to be nearly $3 trillion and up to 80% cases of retinal diseases causing visual impairment or blindness that can often be prevented if detected timely, artificial intelligence opens up a whole new possibilities in eye care. Imaging is non-invasive and reliable screening method but requires expertise to analyse/read the acquired images. Using artificial intelligence, this can be done quickly, yet accurately. RetCAD™ uses state-of-the-art deep learning and computer vision technology utilizing a large amount of retinal images in order to provide precisely quantified clinical evidence. The software assists eye care specialists in early diagnosis and grading of vision threatening diseases, such as Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). Simplified visualization of the scan analysis with heat maps help improve patient engagement and prevent severe eyesight problems and blindness.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out RetCAD on @MedStartr Today #AgeRelatedMacularDegeneration #DiabeticRetinopathy #EyeDisorders #Vision #DiagnosticsScreeningMonitoring #ImagingDiagnostics #Ophthalmology #DigitalDiagnostics #MedMo #MedStartrVentures

https://www.medstartr.ai/s/EbIt3VEsTXk

Get Involved in RetCAD

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2023
Website: retcad.thirona.eu/

Disease Areas

Macular Degeneration Diabetic Retinopathy Eye Disorders Vision

Technologies

Deep LearningComputer VisionMedical Image AnalysisAI/Machine Learning

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of RetCAD?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.